Targeting adenosine for cancer immunotherapy

Targeting adenosine for cancer immunotherapy

Abstract Immune checkpoint antagonists (CTLA-4 and PD-1/PD-L1) and CAR T-cell therapies generate unparalleled durable responses in several cancers and have firmly established immunotherapy as a new pillar of cancer therapy. To extend the impact of immunotherapy to more patients and a broader range o...

Full description

Bibliographic Details
Main Authors: Robert D. Leone, Leisha A. Emens
Format: Article
Language:English
Published: BMJ Publishing Group 2018-06-01
Series:Journal for ImmunoTherapy of Cancer
Subjects:
Adenosine
A2a receptor
Checkpoint blockade
PD-1
Immunotherapy
CD39
Online Access:http://link.springer.com/article/10.1186/s40425-018-0360-8

Internet

http://link.springer.com/article/10.1186/s40425-018-0360-8

Similar Items